Inovio announces peer-reviewed data from INO-3107 study

Inovio (INO) announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title “DNA Immunotherapy. Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis.” The data demonstrate that a majority of patients experienced continued improvement, as measured by the number of surgical procedures needed after treatment with INO-3107, beyond the initial 12-month study period of the previously published Phase 1/2 trial. “The most important takeaway from this data is that the majority of patients experienced a reduction in surgeries following initial treatment with INO-3107, and almost all of those patients maintained or improved their response 2 years after initial treatment,” said Aaron Friedman, Associate Professor of Clinical Otolaryngology, Head and Neck Surgery, University of Cincinnati Medical Center, and a principal investigator on the trial. “With this continued improvement in clinical effect, we believe INO-3107 has the potential to change the trajectory of a patient’s disease and set a new standard of care for the RRP community.” Key Results of the Retrospective Trial with INO-3107 iinclude continued clinical effect against RRP that improved over time; Patients experiencing a 50-100% reduction in surgeries increased from 72% at the end of the initial 12-month Phase 1/2 trial to 86% at the end of the second 12-month period.